Akari Therapeutics grants director conditional stock awards

The grants are subject to forfeiture unless shareholders approve a proposed increase to the equity incentive plan’s share reserve.

Rhea-AI Filing Summary

Akari Therapeutics Plc reported direct awards to director and 10% owner Hoyoung Huh: an RSU award reported for 17,249 ADSs on August 18, 2026, and one for 6,160 ADSs on October 5, 2026. Both were granted in lieu of accrued but unpaid cash retainers payable to directors, are subject to forfeiture if Shareholder Approval of a proposed equity incentive plan amendment to increase the plan’s share reserve is not obtained, and vest in full on the approval date. On August 18, 2026, Huh also received options covering 30,000 ADSs and 15,000 ADSs, each with a $7.8990 exercise price and subject to the same approval condition. The options have different vesting schedules, require continued service on each vesting date, and expire August 18, 2036.

Insider Trade Summary

Grant/Award: 68,409 shares

Grant/Award 4 txns

Insider Huh Hoyoung

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	American Depositary Shares representing Ordinary Shares F2, F3	6,160	$7.899	$49K
Grant/Award	Stock Option (Right to Buy) F4	30,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F5	15,000	$0.00	$0.00
Grant/Award	American Depositary Shares representing Ordinary Shares F1, F3	17,249	$7.899	$136K

Holdings After Transaction: Stock Option (Right to Buy) — 45,000 contracts (Direct); American Depositary Shares representing Ordinary Shares — 140,805 shares (Direct)

Footnotes (5)

1. F1. These American Depositary Shares ("ADSs") represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on August 18, 2026, and is subject to forfeiture if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan ("Shareholder Approval") is not obtained. The RSUs will vest in full on the date of Shareholder Approval.
2. F2. These ADSs represent RSUs, with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on October 5, 2026, and is subject to forfeiture if Shareholder Approval is not obtained. The RSUs will vest in full on the date of Shareholder Approval.
3. F3. This award of RSUs was granted in lieu of accrued but unpaid cash retainers payable to non-execute directors in accordance with the Issuer's remuneration policy.
4. F4. On August 18, 2026, the Reporting Person was granted an option to purchase 30,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. The option will vest with respect to 4.17% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the two-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
5. F5. On August 18, 2026, the Reporting Person was granted an option to purchase 15,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. Beginning on the date of Shareholder Approval, this option will vest with respect to 8.33% of the grant on the date of Shareholder Approval plus 8.33% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the one-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Key Figures

RSU award: 17,249 ADSs RSU award: 6,160 ADSs Option grant: 30,000 ADSs +5 more

8 metrics

RSU award 17,249 ADSs Reported August 18, 2026

RSU award 6,160 ADSs Reported October 5, 2026

Option grant 30,000 ADSs Granted August 18, 2026

Option grant 15,000 ADSs Granted August 18, 2026

Exercise price $7.8990 per ADS Applies to both option grants

Option vesting portion 4.17% For each one-month anniversary elapsed before Shareholder Approval on the 30,000-ADS option

Option vesting portion 8.33% Approval-date portion and each prior monthly anniversary for the 15,000-ADS option

Option expiration August 18, 2036 Both option grants

Key Terms

restricted stock units, forfeiture, cash retainers, vest

4 terms

restricted stock units financial

"These ADSs represent restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

forfeiture technical

"subject to forfeiture if Shareholder Approval is not obtained"

cash retainers financial

"in lieu of accrued but unpaid cash retainers"

vest financial

"The RSUs will vest in full on the date of Shareholder Approval"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did AKTX director Hoyoung Huh report?

Hoyoung Huh reported an RSU award for 17,249 ADSs on August 18, 2026, another for 6,160 ADSs on October 5, 2026, and options for 30,000 ADSs and 15,000 ADSs on August 18, 2026. The RSU grants were made in lieu of accrued but unpaid cash retainers payable to directors.

How do Hoyoung Huh’s AKTX options vest?

The 30,000-ADS option vests at 4.17% for each one-month anniversary of August 18, 2026 that elapsed before Shareholder Approval; the remainder vests in equal monthly installments beginning on the 18th day of the month after approval, until the two-year anniversary of August 18, 2026. The 15,000-ADS option has an 8.33% approval-date portion plus 8.33% for each prior monthly anniversary, with the remainder vesting in equal monthly installments until the one-year anniversary of August 18, 2026. Both schedules require continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/16/2026 - 05:20 PM EDT Accepted by SEC EDGAR 10/16/2026 - 05:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huh Hoyoung

(Last) (First) (Middle)

C/O AKARI THERAPEUTICS PLC

401 EAST JACKSON STREET, SUITE 3300

(Street)

TAMPA FLORIDA 33602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares representing Ordinary Shares	08/18/2026		A		17,249(1)(3)	A	$7.899	134,645	D
American Depositary Shares representing Ordinary Shares	10/05/2026		A		6,160(2)(3)	A	$7.899	140,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.899	08/18/2026		A		30,000		(4)	08/18/2036	American Depositary Shares representing Ordinary Shares	30,000	$0	30,000	D
Stock Option (Right to Buy)	$7.899	08/18/2026		A		15,000		(5)	08/18/2036	American Depositary Shares representing Ordinary Shares	15,000	$0	15,000	D

Explanation of Responses:

1. These American Depositary Shares ("ADSs") represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on August 18, 2026, and is subject to forfeiture if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan ("Shareholder Approval") is not obtained. The RSUs will vest in full on the date of Shareholder Approval.

2. These ADSs represent RSUs, with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of Directors of the Issuer on October 5, 2026, and is subject to forfeiture if Shareholder Approval is not obtained. The RSUs will vest in full on the date of Shareholder Approval.

3. This award of RSUs was granted in lieu of accrued but unpaid cash retainers payable to non-execute directors in accordance with the Issuer's remuneration policy.

4. On August 18, 2026, the Reporting Person was granted an option to purchase 30,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. The option will vest with respect to 4.17% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the two-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

5. On August 18, 2026, the Reporting Person was granted an option to purchase 15,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. Beginning on the date of Shareholder Approval, this option will vest with respect to 8.33% of the grant on the date of Shareholder Approval plus 8.33% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the one-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

	/s/ Abizer Gaslightwala, as Attorney-in-Fact	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)